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Nonagenarians and centenarians represent a quickly growing age group worldwide. In parallel, the prevalence of dementia
increases substantially, but how to define dementia in this oldest-old age segment remains unclear. Although the idea that the risk
of Alzheimer’s disease (AD) decreases after age 90 has now been questioned, the oldest-old still represent a population relatively
resistant to degenerative brain processes. Brain aging is characterised by the formation of neurofibrillary tangles (NFTs) and senile
plaques (SPs) as well as neuronal and synaptic loss in both cognitively intact individuals and patients with AD. In nondemented
cases NFTs are usually restricted to the hippocampal formation, whereas the progressive involvement of the association areas in
the temporal neocortex parallels the development of overt clinical signs of dementia. In contrast, there is little correlation between
the quantitative distribution of SP and AD severity. The pattern of lesion distribution and neuronal loss changes in extreme aging
relative to the younger-old. In contrast to younger cases where dementia is mainly related to severe NFT formation within adjacent
components of the medial and inferior aspects of the temporal cortex, oldest-old individuals display a preferential involvement
of the anterior part of the CA1 field of the hippocampus whereas the inferior temporal and frontal association areas are relatively
spared. This pattern suggests that both the extent of NFT development in the hippocampus as well as a displacement of subregional
NFT distribution within the Cornu ammonis (CA) fields may be key determinants of dementia in the very old. Cortical association
areas are relatively preserved. The progression of NFT formation across increasing cognitive impairment was significantly slower in
nonagenarians and centenarians compared to younger cases in the CA1 field and entorhinal cortex. The total amount of amyloid
and the neuronal loss in these regions were also significantly lower than those reported in younger AD cases. Overall, there is
evidence that pathological substrates of cognitive deterioration in the oldest-old are diﬀerent from those observed in the younger-
old. Microvascular parameters such as mean capillary diameters may be key factors to consider for the prediction of cognitive
decline in the oldest-old. Neuropathological particularities of the oldest-old may be related to “longevity-enabling” genes although
little or nothing is known in this promising field of future research.
1. Introduction
The rapid growth of the world population’s oldest-old age
segment has prompted awareness of age-related diseases
including dementia as well as considerable interest in the
study of the aging human brain. By 2020, people older
than 60 years will account for more than 20% of the total
population with those individuals reaching very old ages
corresponding to the fastest growing age group worldwide.
Rare at the beginning of the 20th century in Switzerland
with about 650 people aged 90 or more, a steady increase
occurred with a total of 2000 oldest-old persons by 1945.
Near exponential growth of this oldest-old group occurred
after 1945 with the total number of oldest-old citizens
amounting to 47000 by 2001, that is, a multiplication of 25
in 56 years [1]. The number of centenarians was multiplied
by 66 since 1950. The Swiss Federal Oﬃce for Statistics
predicts between 90000 and 100000 persons over 90 years
by 2040 and between 110000 and 146000 by 2060 with life
expectancy in women possibly reaching 90 years. Similarly,
the number of centenarians increases steadily in France, the
USA, New Zealand, Japan (for review see [2–4]), and also in
the African American community notwithstanding a lower
life expectancy at birth [5].
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Our ancestral fascination for extreme aging and the
steady increase of the number of centenarians worldwide
prodded the research community to look into psychobio-
logical particularities of the “longevity outliers”. The known
socio demographic predictors of mortality such as smoking
and obesity are less important in this age group [6–
11]. Centenarians may be less prone to oxidative stress
and have better nutritional status, immunologic profile,
endocrinologic and metabolic characteristics than younger
elderly cohorts [12, 13]. The oldest-old may have on average
a better health with a rapid terminal decline relative to those
who die earlier [14]. They report greater satisfaction with life
and social and family relations and display lower scores for
anxiety and depression and better coping abilities compared
to younger-old individuals [15]. In the oldest-old, good
health is associated with greater intellectual activity, while
greater social activity was predicted by extraversion and,
interestingly, negative life events [16]. Thus, centenarians
may form a select cohort with relatively slow rates of aging
and increased resistance to biological and psychological
stress.
2. Dementia in the Oldest-Old
Life expectancy with or without incapacity has increased
markedly: some subjects may remain independent for long
periods into older age while others require help and care
over extended periods of their lives. In Switzerland, the
proportion of persons living in nursing homes increases from
only 5% for those below 80 years to 40% for those between
90 and 94 years of age. Dementia clearly contributes to this
reality. However, it remains unclear how to define dementia
in the frail oldest-old and what it means to be a dementia-
free centenarian despite the claim of some researches that
up to a quarter of all centenarians may be cognitively
intact [17, 18]. Thus, it does not come as a surprise that
trustworthy prevalence and incidence data are still scarce
in the oldest-old age group. In a community sample of
250000 people, 17 centenarians were traced down and 15
could be examined of whom all had cognitive impairment
with a CDR ranging from 1 to 3 [19]. The authors’ most
conservative estimation of dementia in those 100 years old or
more amounted to 88%. Very old age has long been thought
to be associated with the highest prevalence of dementia
[19–21]. More recent epidemiological and clinical studies
in larger cohorts of very old individuals showed prevalence
rates which varied widely. This variability suggests, on the
one hand, that substantial methodological diﬃculties remain
and, on the other hand, that dementia is not inevitable in
very old individuals (for review see [2, 17]) and may even
decrease after age 90 [22–24]. However, the pendulum is
currently swinging back and preliminary results now indicate
that dementia and AD continue to rise also at very high
ages with both incidence and prevalence of dementia being
highest in the oldest-old [25, 26]. Although further studies
with better operational criteria for dementia in the oldest-old
are still needed to settle these controversies, epidemiological
and clinical studies nevertheless indicate that the oldest-
old are likely to be biologically diﬀerent from the younger-
old. The lack of an association between Alzheimer’s disease
(AD) and ApoE4—a known risk factor for late-onset AD in
younger cohorts—in centenarians adds further evidence to
this hypothesis [27–30]. The study of oldest-old individuals
may permit to define the spectrum and extent of changes in
brain morphology that occur with normal brain aging and
assess correlations between the neuropathological definition
of normal brain aging and the clinical development of
dementia [31–33].
3. AD-Related Lesion Distribution Patterns in
the Normal Elderly
Brain aging is characterized by the formation of neurofibril-
lary tangles (NFTs) and senile plaques (SPs) as well as neu-
ronal and synaptic loss in both cognitively intact individuals
and patients with AD. The first cited diagnostic criteria for
AD were intended to aid in the development of uniform
procedures by proposing minimally required SP densities as
a function of age [34, 35]. These recommendations were
not broadly accepted and the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) proposed another
set of standardized neuropathological criteria [36]. These
semiquantitative criteria were determined as a function of
the development of neuritic plaques in three age groups
(less than 50, 50 to 75, and over 75). The diagnosis was
based on a combination of clinical information and an “age-
related plaque score” that reflected the maximal cortical
involvement. This combination yielded a tripartite level of
diagnostic certainty (i.e., definite, probable, or possible AD).
However, the lesion load in the hippocampal formation
was not entered into the diagnostic algorithm despite its
involvement in the pathogenesis of AD. At that, CERAD
criteria have been inspired somewhat unilaterally by the
amyloid cascade hypothesis and do not consider NFT
densities in the neocortex, even though the latter correlate
better with the severity of dementia. In other words, severe
SP formation may take place in the neocortex in the presence
of only very mild cognitive impairment (for review see [37,
38]). Furthermore, the central pathological hallmark of AD,
that is, NFT, is found in subjects with no significant cognitive
impairment. Indeed, there is a significant overlap in NFT and
neuritic plaques burden between cognitively impaired and
cognitively intact individuals [39]. Thus, in 97 nondemented
people with a mean age of 84 years, about 40% met at least
some level of and 20% strict criteria for neuropathological
criteria for AD [40]. Clearly, the clinical significance of NFT
is not unequivocal and other pathological predictors are
likely to exist of which reduced neuron number appears to
be a candidate. Indeed, stereological analyses have revealed
age-related decreases in total neuron number of 30% and
50% in the dentate hilus of the hippocampus and subiculum,
respectively, between ages 13 and 85. Conversely, no neuronal
loss was found in CA1-3 fields and entorhinal cortex during
normal aging in contrast to AD [41–43]. In normal aging,
there is no additional depletion, as in AD, of neuronal cell
bodies in the dentate hilus and subiculum, or a massive
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reduction in the numbers of pyramidal neurons in the CA1
field and layers II and V of the entorhinal cortex [41–
45].
4. Clinicopathological Correlations in
Typical Alzheimer’s Disease
While the definite diagnosis of AD is based on neuropatho-
logical criteria, the clinical diagnosis of probable and possible
AD in clinical settings is usually made according to the
NINCDS-ADRDA criteria [46]. Typical AD is characterized
by an insidious onset and a progressively worsening course
of episodic memory. The most common initial presentation
of AD is that of a progressive amnestic syndrome [47].
Executive, linguistic, visuospatial, and other cognitive deficits
are subsequently grafted upon the primary progressive
memory impairment with functional deficits and increasing
dependency paralleling the course of the cognitive decline.
Prospective studies of large cohorts of patients with typical
AD have shown a prototypical and predictable clinical course
[48] although important atypical variations often occur (for
a review [49]).
In terms of clinicopathological correlations, several lines
of evidence indicate that the primary progressive amnestic
syndrome so characteristic of the initial stages of typical
AD is the consequence of the neuropathological changes in
the medial temporal structures, in particular the entorhinal
cortex and the hippocampus. Although there is still ongoing
controversy as to the exact roles of these structures in
cognition, they are likely to be important in encoding
new information [50–52]. The initial stages of AD are
characterized by NFT spread from the entorhinal cortex to
the hippocampus, corresponding to Braak and Braak stages
1 and 2, which precedes the progressive invasion of the
allocortex and isocortex [53]. The NFT distribution is not
only area-specific but also cell-specific. In the hippocampus,
particularly in the CA1 and CA2 regions, pyramidal cells are
selectively damaged whereas glutamatergic cells degenerate
in the entorhinal cortex presumably interrupting complex
neuronal circuits in the medial temporal lobe that are indis-
pensable for encoding new information [54–57]. Besides
episodic memory deficits, early impairment of olfactory
perception has been described and kindled hope that this
observation might allow early and easy detection of AD [58–
61]. Besides the early damage of the limbic system, previous
clinicopathological studies also revealed strong relationships
between the patterns of NFT distribution and cognitive
deficits in typical AD cases. For instance, constructional
apraxia correlated with NFT densities in Brodmann areas
7 and 18 [62], and other specific correlations were found
for associative visual agnosia [63], naming and identification
of famous faces [64], and spatial disorientation [65]. In
contrast to NFT, SP correlate less well with clinical features
and their presence may be associated with no or only
minimal intellectual changes in the elderly (for a review see
[50–52]).
5. AD-Related Lesion Distribution Patterns in
the Oldest-Old
Most of the above studies have not included very old subjects.
The question, thus, arises whether or not the pattern of lesion
distribution and neuronal loss changes in extreme aging.
5.1. Oldest-Old versus Younger-Old with or without Dementia
(cf. also Table 1 for a Schematic Representation). A recent
study using the CERAD criteria for neuropathological diag-
nosis found a progressive increase of moderate to severe AD-
type pathology with age in subjects between 69 and 103 years
in those without dementia [66]. In the demented, dementia
status is mainly related to severe NFT formation within
adjacent components of the medial and inferior aspects of
the temporal cortex in younger cases whereas oldest-old
individuals with dementia display a preferential involvement
of the anterior part of the CA1 field of the hippocampus
with relative sparing of the inferior temporal and frontal
association areas [44, 67]. The progression of NFT formation
across the diﬀerent CDR groups was significantly slower
in nonagenarians and centenarians (from 1 to 17% in
the entorhinal cortex and 1.7 to 37% in the CA1 field)
compared to recent observations in a series of younger
cases (from 4 to 79% in the entorhinal cortex and 3 to
80% in the CA1 field) [68]. The degree of interindividual
variability for NFT numbers was, however, quite similar
between younger and elderly cohorts [68]. The Oregon brain
aging study on neuropathologic aging and cognitive function
in healthy oldest-old individuals confirmed this pattern of
NFT distribution in the CA1 field [32]. In agreement with
previous observations in centenarian brains [44], even cases
with moderate dementia display only mild NFT formation
in the entorhinal cortex with more than 80% of preserved
neurons. This contrasts with the results of several previous
studies in younger samples which demonstrated that the
entorhinal cortex is more severely aﬀected and involved
earlier in the degenerative process than hippocampal regions
[38, 69–71].
The magnitude of neuronal loss in the entorhinal cortex
and CA1 field in older subjects was significantly lower than
that reported in younger AD cases [45, 58, 68, 72, 73].
Moreover, the extensive neuronal loss in the hippocampal
formation reported in younger AD series [74] appears to be
confined to layer II of the entorhinal cortex in nonagenarians
and centenarians [44]. In this latter group, the number of
layer II entorhinal cortex neurons is thought to decrease by
60% in patients with CDR 0.5 and by 90% in severe AD
cases [45]. In the CA1 field, a depletion of 38% to 69% was
reported [45, 58, 68, 72, 73]. These data imply that, like AD
pathologic changes, neuronal loss is less prominent in the
oldest-old even in the presence of AD [44]. In conjunction
with the observations of only mild synaptic loss and cerebral
amyloid angiopathy in centenarians [75] these findings give
additional support to the notion that the occurrence and
progression of AD-related pathologic changes are not a sine
qua non concomitant of increasing age [32, 44, 76, 77].
Strong relationships between NFT counts and neuron
loss in the hippocampal formation and neocortex have been
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Table 1: Alzheimer’s disease pathology in the cognitively impaired young-old versus oldest-old.
Cognitively impaired young-old subjects Cognitively impaired oldest-old subjects
Senile plaques
Higher amyloid load but lower correlation
with neurone loss and cognitive status
Lower amyloid load but better correlation with
neurone loss and cognitive status
Early and significant CA2-3 involvement Invasion of anterior CA1 field
Early and significant EC involvement Mild invasion of EC
Significant inferior temporal and frontal
associative cortex involvement with increasing
dementia
Relative sparing of inferior temporal and
frontal associative cortex
Neurofibrillary
tangles
Less parietal and cingulate cortex involvement More parietal and cingulate cortex involvement
With advancing dementia, quick invasion of
CA1 andspread to adjacent associative cortex
With advancing dementia, lower invasion of
CA1 and less spread to associative cortex
Higher strength of association with dementia Lower strength of association with dementia
High interindividual variability
Neurones
Loss of pyramidal neurones in CA1 and EC
Less neurone loss in CA1
Possibly, relative sparing of EC neurones
More NFT-related neurone loss Less NFT-related neurone loss
NFT: neurofibrillary tangles; CA: Cornu Ammonis; EC: entorhinal cortex.
reported and suggest that neuronal loss is NFT-dependent
[45]. However, our data reveal a dissociation between the
patterns of progression of NFT and neuronal loss in the
entorhinal cortex and CA1 field [78]. Non-NFT related
mechanisms of neurodegeneration may therefore determine
neuronal depletion in the oldest-old age group [44]. These
mechanisms remain largely speculative, but recent contribu-
tions postulate that apoptosis, oxidative stress and excitotoxic
mechanisms play a key role in inducing neuronal death that
would predate NFT formation in some regions (for review
see [73]).
Unlike younger cohorts where SP formation does not
correlate with neuronal depletion and cognitive status [79–
81], both earlier and more recent studies suggest that SP
densities in the neocortex are related to the degree of
neuronal loss and severe AD in the oldest-old [32, 44].
However, older cases also display significantly lower total
amyloid volume in the areas studied compared to that
reported in younger series (20 mm3 versus 100–800 mm3)
[82].
5.2. Demented Oldest-Old versus Nondemented Oldest-Old (cf.
also Table 2 for a Schematic Representation). As mentioned
above, the association between AD-type pathology and
dementia, in a cohort of 456 subjects between 69 and 103
years was stronger in the younger old persons than in the
older old ones [66]. Oldest-old individuals with dementia
display a preferential involvement of the anterior part of
the CA1 field of the hippocampus with relative sparing of
the inferior temporal and frontal association areas [44, 67].
Thus, NFT development in the hippocampus may be the key
determinant of dementia in the very old. In line with this
view, higher NFT densities were found in the CA1 field of
one demented centenarian as compared to eleven cognitively
intact centenarians [83]. NFT densities in the anterior CA1
but not in the posterior CA1 field and entorhinal cortex, were
significantly diﬀerent between demented and nondemented
very old patients [31, 44, 77]. However, other studies find
evidence for more extensive brain involvement in the oldest-
old with dementia. In a such study of 19 centenarians
including four AD cases, substantial NFT involvement was
present not only in the hippocampus but also the entorhinal
cortex [84].
5.3. Clinicopathological Correlations in the Oldest-Old
5.3.1. AD-Pathology. Several cases with minimal AD pathol-
ogy and preserved cognitive functions [31, 33, 67], so called
“supernormal centenarians”, represent a rare phenotype
relatively protected from AD pathology and bear witness to
successful aging near the upper limit of the human life span.
Recent studies attempted to define the cognitive impact of
NFT, SP, and neuronal loss in this age group. As mentioned,
the strength of the association between overall AD pathology
and dementia declined with age [66]. However, not only
the global lesion load, but also the lesion distribution
may play a role. Thus, AD-related pathology including the
assessment of total NFT, neuron numbers, and amyloid
volume in entorhinal cortex, CA fields, and dentate gyrus
was performed in 12 individuals over 90 years with variable
degrees of cognitive decline [85]. Total neuron numbers and
volumes of reference were fairly consistent among cases. In
fact, the estimates of these variables fall well within the
range of previous stereologic assessments in these regions
from cognitively intact elderly individuals [45, 58, 68, 72, 74,
82, 86]. As mentioned, even cases with moderate dementia
display only mild NFT formation and neuron loss in the
entorhinal cortex while the entorhinal cortex is more severely
aﬀected and involved earlier in the degenerative process than
other hippocampal regions in younger samples [38, 69–71].
Strikingly, correlations between AD pathological hallmarks
in the hippocampal formation and clinical status after 90
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Table 2: Alzheimer’s disease pathology in the oldest-old with versus without cognitive impairment.
Cognitively intact oldest-old subjects Cognitively impaired oldest-old subjects
Senile plaques
Similar lesion load Similar lesion load
Overall, poor correlation with clinical status
No or little invasion of anterior CA1 field Invasion of anterior CA1 field
Similar density in posterior CA1field Similar density in posterior CA1 field
Neurofibrillary
tangles
Similar, mild invasion of EC Similar, mild invasion of EC (controversial)
Possibly less neuritic dystrophy Possibly more neuritic dystrophy
Overall, poor correlation with clinical status
Neurones
Similar neurone counts Similar neurone counts
Overall, poor correlation with clinical status
CA: Cornu Ammonis; EC: entorhinal cortex.
years were poor [85]. Only a modest percentage of the CDR
variability was explained by NFT counts in CA2-3 (18%)
and the dentate gyrus (17%). Neither neuron numbers nor
total amyloid volumes were significantly related to the CDR
score. In spite of the clear neuronal loss observed in cases
with moderate to severe dementia, total neuron numbers
in the entire sample did not significantly predict cognitive
status. Overall, sparing of the entorhinal cortex and CA1
field in the oldest-old relative to younger cohorts suggests
that independent morphometric variables may decisively
contribute to the cognitive decline in this age group.
Indeed, neuritic dystrophy [87] may be a further con-
tributor. Neuropil threads are thought to account for 85-
90% of cortical tau pathology in normal brain ageing [88]
and, thus, they may contribute to cognitive deterioration.
However, neuropil thread formation in the hippocampus did
not appear to be an independent marker of dementia severity
as their length was strongly correlated with NFT numbers
at least in the early stages of the degenerative process in the
oldest-old [89]. Progression of hippocampal and entorhinal
tau burden was associated with dementia status, but this
eﬀect disappeared when adjusted for Braak and Braak stages
[90].
5.4. Other Pathological Changes. Synaptic loss may be an
important factor [87]. Recently, significant hypertrophy of
the cell bodies, nuclei, and nucleoli in the CA1 neurons was
found in elderly nuns with normal cognition but substantial
AD-type lesions suggesting that neuronal hypertrophy may
constitute an early cellular response to AD or reflect com-
pensatory mechanisms [91]. Structural parameters of the
cerebral vasculature such as perivascular collagen deposits,
atrophy of endothelium, basement membrane thickening
and pericyte degeneration as well as qualitative changes
in microvascular structure (such as glomerular loops and
twisted capillaries) as described both in the aging brain
and in AD oﬀer themselves as still further contributors to
cognitive decline (for review see [87, 92–95]). Quantitative
analyses of structural parameters such as capillary density,
diameters, or length led to controversial data [96–103]. The
development of modern design-based stereological tech-
niques allowed for a more accurate assessment of age-related
changes in the capillary network [104, 105] and open up
this field of study to nonagenarians and centenarians. In 19
very old individuals with various degrees of cognitive impair-
ment, both mean diameters and total capillary numbers,
but not total capillary length and capillary morphological
parameters, were strongly related to total neuron numbers
in the CA1 field and entorhinal cortex [106]. These results
suggest a relationship between microvascular changes and
AD-related neuronal depletion. Disruption of the balance
between energy requirements and cerebral blood supply
rendering the brain more vulnerable to oxidative stress
damage and ultimately neuronal death may explain this
link [93, 107–109]. Mean capillary diameters in the CA1
field and entorhinal cortex explained respectively 19% and
31.1% of the CDR scores, an association that persisted
after adjustment for total neuron numbers, NFT numbers,
or amyloid volume [106]. Instead of the recruitment of
additional capillaries, increased cognitive load may induce
diﬀerential distribution of flow [110], heterogeneity in blood
flow velocity [111], and changes in capillary diameter [112].
In the longitudinal Oregon Brain Aging study, NFT and
SP densities in neocortical areas were significantly related to
cognitive scores [32]. Overt clinical signs of AD in oldest-
old individuals appears to require a progressive damage of
areas 7, 22, 23 and 24 suggesting a displacement of NFT, such
that parietal and cingulate cortex are more aﬀected than is
usually the case in AD, whereas superior frontal and inferior
temporal association areas are relatively preserved [44, 71].
6. Conclusions
The controversy over the continuity versus discontinuity
between normal brain aging and dementia goes on. The
hypothesis that AD is an ageing-related condition is sup-
ported by the nearly ubiquitous presence of AD pathologic
changes in the course of brain aging and the exponential
increase of AD prevalence after 65 years of age. However,
contrasting with this view of the aging process, the study
of oldest-old individuals indicates that the occurrence of
AD pathology is not a mandatory phenomenon of increas-
ing chronologic age. In particular, the neuropathology of
advanced aging strongly suggests that very old individuals
6 Current Gerontology and Geriatrics Research
with AD display a striking resistance to the neurodegen-
erative process with only mild neuronal loss in the hip-
pocampal formation. Our hospital-based findings support a
dissociation between the clinical expression and traditionally
assessed AD pathology. These findings are consistent with the
recent neuropathological observations of the New England
Centenarian Study [8, 113] and show the limits of the lesional
model for explaining the expression of dementia symptoms
in this particular age group. Furthermore, they oﬀer a new
perspective in the field of clinicopathological correlations
by revealing the cognitive impact of decreased capillary
diameter, a structural but not lesional parameter of the aging
brain. Similarly, we are not to forget changes at the cellular
level reflecting both early cell stress to AD or compensatory
mechanisms [91]. A further conclusion stemming from the
observation of a looser association between AD-pathology
and dementia in the oldest-old suggests the necessity to adapt
current neuropathological criteria for the diagnosis of AD in
this age group [114].
The biological background of the increased resistance
to AD lesion development after 90 years is still poorly
understood. Oldest-old people may show genetic variations
that influence basic mechanisms of brain aging resulting in
a decreased susceptibility to age-associated diseases [115].
In particular, the oldest-old may lack “disease genes” that
predispose to fatal age-related diseases [116], or, alterna-
tively, have so called “longevity-enabling” genes that confer
protection against age-related illnesses and constitute future
therapeutic targets to delay late-onset dementia [117, 118].
The sparing of CA1 field and entorhinal cortex in the
oldest-old may be related to a genetically determined resis-
tance of these neuronal subpopulations in very old people.
Two candidate genes predisposing to longevity related to
lipoprotein synthesis have been identified and suggest that
protection against cardiovascular diseases may be primordial
to achieve extreme old age [119–121]. Although the relation-
ship between these vascular “longevity-enabling” genes and
AD-related pathology is not clear, the link between preserved
cognition and brain capillary diameter points to the need
for exploring the genetic determinants of the microvascular
system in very old individuals as well as possible links
with compensatory mechanisms at the cellular level [91].
The development of structural investigation methods at
the microscopic level in combination with diﬀerential gene
expression studies may provide the future basis for a better
understanding of longevity.
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